LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Fulgent Genetics Inc

Slēgts

SektorsVeselības aprūpe

22.28 0.18

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

21.9

Max

22.33

Galvenie mērījumi

By Trading Economics

Ienākumi

-7.4M

-19M

Pārdošana

8.3M

82M

Peļņas marža

-23.539

Darbinieki

1,313

EBITDA

-3.5M

-15M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+12.76% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

130M

679M

Iepriekšējā atvēršanas cena

22.1

Iepriekšējā slēgšanas cena

22.28

Ziņu noskaņojums

By Acuity

76%

24%

351 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Fulgent Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. sept. 23:59 UTC

Iegādes, apvienošanās, pārņemšana

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025. g. 8. sept. 22:02 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Tron Shares Rise After New Investment From Bravemorning

2025. g. 8. sept. 16:14 UTC

Galvenie tirgus virzītāji

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025. g. 8. sept. 16:13 UTC

Galvenie tirgus virzītāji

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025. g. 8. sept. 22:56 UTC

Tirgus saruna

Worst May Be Over for New Zealand Retailers -- Market Talk

2025. g. 8. sept. 22:23 UTC

Tirgus saruna

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025. g. 8. sept. 21:51 UTC

Tirgus saruna

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025. g. 8. sept. 21:47 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4B AI Deal With Nebius

2025. g. 8. sept. 21:33 UTC

Iegādes, apvienošanās, pārņemšana

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025. g. 8. sept. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025. g. 8. sept. 21:19 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025. g. 8. sept. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025. g. 8. sept. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 19:33 UTC

Tirgus saruna

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025. g. 8. sept. 19:22 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025. g. 8. sept. 19:02 UTC

Tirgus saruna

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025. g. 8. sept. 17:29 UTC

Tirgus saruna

Mexican Inflation Seen Little Changed in August -- Market Talk

2025. g. 8. sept. 16:59 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025. g. 8. sept. 16:36 UTC

Tirgus saruna

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025. g. 8. sept. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 16:16 UTC

Peļņas

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025. g. 8. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 8. sept. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Fulgent Genetics Inc Prognoze

Cenas mērķis

By TipRanks

12.76% augšup

Prognoze 12 mēnešiem

Vidējais 24.75 USD  12.76%

Augstākais 30 USD

Zemākais 21 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Fulgent Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

17.32 / 19.04Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Neutral Evidence

Noskaņojums

By Acuity

351 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat